Results 41 to 50 of about 183,390 (190)

Subtype-Specific HIV-1 Protease and the Role of Hinge and Flap Dynamics in Drug Resistance: A Subtype C Narrative

Viruses
The HIV-1 aspartic protease is an effective target for the treatment of HIV/AIDS. Current therapy utilizes a selection of nine protease inhibitors (PIs) in combination with other classes of antiretroviral drugs.
Dean Sherry, Zaahida Sheik Ismail, Tshele Mokhantso, Yasien Sayed   +3 more
doaj   +1 more source

Molecular Basis for Drug Resistance in HIV-1 Protease

Viruses, 2010
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the ...
Celia A. Schiffer, Kelly Thayer, Ellen A. Nalivaika, Ayşegül Özen, Moses M. Prabu-Jeyabalan, Madhavi N.L. Nalam, Nancy M. King, Rajintha M. Bandaranayake, Jennifer F. Murzycki, Seema Mittal, Madhavi Kolli, Yufeng Cai, Akbar Ali   +12 more
doaj   +1 more source

Prediction and molecular field view of drug resistance in HIV-1 protease mutants

Scientific Reports, 2022
Conquering the mutational drug resistance is a great challenge in anti-HIV drug development and therapy. Quantitatively predicting the mutational drug resistance in molecular level and elucidating the three dimensional structure-resistance relationships ...
Baifan Wang, Yinwu He, Xin Wen, Zhen Xi
doaj   +1 more source

Metabolic and cardiac adaptation to chronic pharmacologic blockade of facilitative glucose transport in murine dilated cardiomyopathy and myocardial ischemia [PDF]

, 2018
GLUT transgenic and knockout mice have provided valuable insight into the role of facilitative glucose transporters (GLUTs) in cardiovascular and metabolic disease, but compensatory physiological changes can hinder interpretation of these models.
Heitmeier, Monique R., Hresko, Richard C., Hruz, Paul W., Jay, Patrick Y., Kovacs, Attila, Payne, Maria A., Weinheimer, Carla   +6 more
core   +2 more sources

HIV-1 CRF 02 AG polymerase genes in Southern Ghana are mosaics of different 02 AG strains and the protease gene cannot infer subtypes

Virology Journal, 2009
Background Little is known about the detailed phylogeny relationships of CRF 02_AG HIV-1 polymerase genes in Ghana. The use of the protease gene of HIV-1 for subtyping has shown conflicting results. Methods The partial polymerase gene sequences of 25 HIV-
Sagoe Kwamena W, Dwidar Magda, Adiku Theophilus K, Arens Max Q   +3 more
doaj   +1 more source

Adaptive HIV-1 evolutionary trajectories are constrained by protein stability [PDF]

, 2017
Despite the use of combination antiretroviral drugs for the treatment of HIV-1 infection, the emergence of drug resistance remains a problem. Resistance may be conferred either by a single mutation or a concerted set of mutations.
Kandathil, Shaun M., Lovell, Simon C., Olabode, Abayomi S., Robertson, David L.   +3 more
core   +2 more sources

HIV-1 Protease Inhibitors From Marine Brown Alga: A Literature Review [PDF]

, 2017
The human immunodeficiency virus type 1 (HIV-1) causes an infectious disease that if left untreated can progress to acquired immunodeficiency syndrome (AIDS) and be fatal.
Nunez Aguilar, Eric
core   +1 more source

HIV-1 protease-induced apoptosis [PDF]

Retrovirology, 2014
Apoptosis is one of the presumptive causes of CD4+ T cell depletion during HIV infection and progression to AIDS. However, the precise role of HIV-1 in this process remains unexplained. HIV-1 protease (PR) has been suggested as a possible factor, but a direct link between HIV-1 PR enzymatic activity and apoptosis has not been established.Here, we show ...
Rumlová, Michaela, Křížová, Ivana, Keprová, Alena, Hadravová, Romana, Doležal, Michal, Strohalmová, Karolína, Pichová, Iva, Hájek, Miroslav, Ruml, Tomáš   +8 more
openaire   +2 more sources

Virological outcomes of second-line protease inhibitor-based treatment for human immunodeficiency virus type 1 in a high-prevalence rural South African setting: a competing-risks prospective cohort analysis [PDF]

, 2017
Background. Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV ...
2LADY Study Group, Alexandra Calmy, Anne Derache, ANRS 12249 TasP Study Group, Collins Iwuji, Dami Collier, DART Virology Group and Trial Team, Deenan Pillay, EARNEST Trial Team, Francois Dabis, National Department of Health, National Department of Health, Nonhlanhla Okesola, PharmAccess African Studies to Evaluate Resistance (PASER), PharmAccess African Studies to Evaluate Resistance (PASER), Ravindra K. Gupta, SECOND-LINE, SECOND-LINE Study Group, Southern African Treatment and Resistance Network, TenoRes Study Group, Tulio de Oliveira, World Health Organization, World Health Organization   +22 more
core   +3 more sources

Zero prevalence of primary drug resistance-associated mutations to protease inhibitors in HIV-1 drug-naive patients in and around Aligarh, India

Journal of Infection in Developing Countries, 2014
Introduction: This study aimed to evaluate the prevalence of resistance mutations in the protease gene of HIV-1 strains isolated from north Indian antiretroviral (ARV) treatment-naive patients and to assess the phylogenetic relatedness of these strains ...
Mohd Azam, Abida Malik, Meher Rizvi, Arvind Rai   +3 more
doaj   +1 more source